NAMS NewAmsterdam Pharma Corp: Rasio rega marang prakiraan pendapatan

NewAmsterdam Pharma - logo grafis emiten NAMS

NewAmsterdam Pharma's success is based on clinical test results and regulatory approval of its cardiology products. The company's forward P/S trend confirms these expectations, with the current figure standing at 93.20. Growth is constrained by pressure from low-cost generics and the influence of industry behemoths, yet production stability is ensured through diversified raw material supply chains across various regions.

NewAmsterdam Pharma Company N.V. - Rasio kapitalisasi marang dodolan sing dikarepake NAMS (periode 21.06.2023 - 15.11.2026)

Ringkesan rincian data analitis newamsterdampharma.com (NAMS)

Pambiji fundamental perusahaan:newamsterdampharma.com NAMS
Produk asli NewAmsterdam Pharma

Forward P/S is calculated as the ratio of current market capitalization to expected revenue for a future period, measuring the market premium for sales growth potential. Analyzing the historical forward P/S for NewAmsterdam Pharma (NAMS) allows for an assessment of the company's valuation fairness, considering its patents and expansion into the inelastic cholesterol medication market, where high coefficient stability confirms long-term margin sustainability.

Analisis pesaing

Rasio rega marang prakiraan pendapatan ascendispharma.com ASND|Madrigal Corp (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MTSR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MoonLake Corp|Crinetics Corp (CRNX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan soleno.life (SLNO)|Multiplikator forward rega marang pendapatan Amicus Therapeutics FOLD|Rega forward marang dodolan 89bio Inc|Multiplikator Forward P/S Agios Pharmaceuticals, Inc. AGIO|GPCR: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake MiMedx Corp MDXG|RZLT (Rezolute Corp) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan LXRX|MBX (MBX Biosciences) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Altimmune Inc (ALT)|Multiplikator forward rega marang pendapatan AARD (Aardvark Therapeutics Corp)|Multiplikator forward rega marang pendapatan Sagimet SGMT|Multiplikator Forward P/S BIOA (BioAge Labs)|Multiplikator Forward P/S Biomea Fusion BMEA|QNCX: Multiplikator forward rega marang pendapatan|GUTS: Rasio rega marang prakiraan pendapatan|vTv Therapeutics Inc (VTVT) - Rasio rega marang prakiraan pendapatan|ATPC: Rasio rega marang pendapatan sing dikarepake|PLUR (pluri-biotech.com) - Multiplikator Forward P/S|SYBX: Rega forward marang dodolan|Multiplikator Forward P/S LPCN|Rasio kapitalisasi marang dodolan sing dikarepake Matinas BioPharma Holdings, Inc.|Rasio rega marang prakiraan pendapatan Spruce Biosciences Inc. SPRB|GLTO - Multiplikator forward rega marang pendapatan|CTCX - Rasio rega marang prakiraan pendapatan|LUMO - Multiplikator Forward P/S|ONVO: Multiplikator Forward P/S|RDUS (Radius Recycling) - Rasio rega marang prakiraan pendapatan